Products from TransMed7's technology pipeline currently under development are designed to address critical healthcare needs in medical fields such as breast health; soft tissue surgery, including small or fragile tissues and challenging surgical spaces, with endoscopy, laparoscopy, and robotics applications; bone marrow biopsy and harvest; interventional cardiology; and minimally invasive peripheral vascular procedures.
"This new strategic partnership with Peridot enables TransMed7 to launch new products such as our Concorde and Martinet technologies directly into the market immediately following FDA clearance. Peridot was our contract manufacturer for our SpeedBird platform needle sets, and we are excited to be expanding our relationship with Peridot for timed product commercial release in significant quantities for strategic market penetration," said Eugene H. Vetter, TransMed7's Co-Founder and CEO.
TransMed7 is focused on the development of minimally invasive medical devices. With particular expertise in both oncologic and cardiovascular disease, the company and its team of clinicians, scientists, and engineers have developed a portfolio of next-generation platform devices.
Peridot offers complete end-to-end precision manufacturing and clean room assembly services to a wide range of industries. With over twenty years' experience with device fabrication and precision miniature and micro-miniature component assembly, the company can design, prototype, test and deliver products with precision and versatility.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval